Community post

Felix Biotechnology has been awarded a Small Business Innovation Research (SBIR) Phase I grant for $314,411 from the National Institute of Health (NIH) to develop a microfluidics platform for rapid, high-throughput screening of therapeutic bacteriophages that target disease-causing bacteria.